department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

pharmadog news

Browse

811 stories matching this filter · ← front page

★ save view ↓export CSV

rangeto

sort

recent oldest source alpha

source

STAT785 Endpoints586 BioPharma Dive224 onclive165 BioSpace60 Fierce Biotech59 raps24

therapy area

all Oncology81 Cardiology27 Psychiatry & CNS21 Vaccines17 Immunology17 Rare Disease12 Hepatology6

<![CDATA[Future Directions in Relapsed and Refractory Multiple Myeloma ]]>
<![CDATA[]]>
onclive · 2mo ago↗ source
<![CDATA[Dr Parikh on the Feasibility and Importance of Immunotherapy Trials in Anal Cancer ]]>
<![CDATA[Aparna R. Parikh, MD, discusses how trials like PODIUM-303 are reshaping the treatment paradigm for squamous cell anal carcinomas. ]]>
onclive · 2mo ago↗ source
<![CDATA[Sequencing Strategies After Progression in Multiple Myeloma ]]>
<![CDATA[]]>
onclive · 2mo ago↗ source

page 24 of 33

Infectious Disease4

<![CDATA[EGFR-Mutated NSCLC: Targeting MET-Driven Resistance in Second-Line Therapy]]>

<![CDATA[In this segment, Dr. Sands asks Dr. Wakelee to discuss how emerging data on MET-driven resistance mechanisms are shaping second-line treatment decisions in EGFR-mutated non-small cell lung…

onclive · 2mo ago↗ source

<![CDATA[Sequencing ADCs in Endometrial Cancer]]>

<![CDATA[Sequencing therapy in recurrent endometrial cancer is becoming more complicated as immunotherapy moves earlier and antibody drug conjugates gain momentum.]]>

onclive · 2mo ago↗ source

<![CDATA[Second Clinical Scenario - Progressive Disease Despite Hematocrit Control]]>

<![CDATA[Polycythemia vera symptoms like fatigue and aquagenic itching signal active disease; experts urge objective tracking and tailored therapy beyond phlebotomy.]]>

onclive · 2mo ago↗ source

Flagship startup Serif says it has solved non-viral gene therapy in monkeys

BOSTON — Serif Biomedicines, a startup launched last month by Flagship Pioneering, believes it has solved two technical challenges that have long prevented gene therapy from being delivered without…

Endpoints · 2mo ago↗ source

Bristol Myers joins Hengrui party in 13-asset deal worth up to $15.2B

It's becoming Hengrui Pharma's world, and some Western drugmakers are just living in it. China's largest pharma company, which boasts one of the biggest pipelines in the industry, has lined up Br…

Endpoints · 2mo ago↗ source

<![CDATA[Real-World Data Highlight Survival Benefit of Rituximab Maintenance After Frontline BR in MCL]]>

<![CDATA[Rituximab following first-line bendamustine demonstrated significant OS and EFS real-world benefits in mantle cell lymphoma.]]>

onclive · 2mo ago↗ source

<![CDATA[Dr Silbermann on Clinical Trial Design Considerations in Multiple Myeloma]]>

<![CDATA[Rebecca Silbermann, MD, MMS, outlines key trial design considerations in multiple myeloma, including supportive care measures and end point selection.]]>

onclive · 2mo ago↗ source

Optum Rx unveils pharmacy model with clear fees, building on transparency push

UnitedHealth Group’s Optum Rx on Monday unveiled a new approach to prescription drug benefits that it said offers its customers transparency into the entire drug supply chain. Under the new model…

Endpoints · 2mo ago↗ source

<![CDATA[Retrospective Data Show Potential Real-World TTNT and OS Improvements With Next-Generation BTK Inhibitors in R/R MCL]]>

<![CDATA[Retrospective data showed zanubrutinib was associated with improved real-world overall survival vs ibrutinib in second- or third-line mantle cell lymphoma.]]>

onclive · 2mo ago↗ source

Rezdiffra is exceeding Wall Street's expectations as the MASH market takes shape

It seems there’s room for two in the MASH market. When Novo Nordisk’s blockbuster weight loss drug Wegovy won approval in August 2025 to treat the fatty liver disease, some investors thought it w…

Endpoints · 2mo ago↗ source

<![CDATA[MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumors]]>

<![CDATA[Roswell Park Comprehensive Cancer Center launched a phase 2 trial evaluating SurVaxM plus temozolomide in progressing neuroendocrine tumors.]]>

onclive · 2mo ago↗ source

<![CDATA[INBRX-106 Plus Pembrolizumab Yields Efficacy Benefit vs Pembrolizumab Alone in First-Line HNSCC]]>

<![CDATA[First-line INBRX-106 plus pembrolizumab generated a higher ORR vs pembrolizumab monotherapy in PD-L1–positive metastatic or unresectable HNSCC.]]>

onclive · 2mo ago↗ source

Daiichi eyes almost $15B in oncology sales by 2030 in ADC franchise push

Daiichi Sankyo is betting on its oncology franchise to push it past 3 trillion Japanese yen ($19 billion) in 2030 revenues. The drugmaker published a new five-year business plan on Monday ...

Endpoints · 2mo ago↗ source

New home for Novo's Parkinson's cell therapy; GSK's deal to sell drug in China

Plus, label expansions for two drugs targeting rare diseases, and Genmab scraps a Phase 1 cancer trial: 🧠 Novo's Parkinson's cell therapy finds a biotech home: Novo Nordisk has found a home for…

Endpoints · 2mo ago↗ source

Inhibrx says combo therapy shrank more tumors than Merck's Keytruda alone

San Diego-based biotech Inhibrx is claiming that it outperformed Merck’s Keytruda in a difficult-to-treat cancer. The combination of Keytruda and Inhibrx’s experimental drug INBRX-106 shrank more…

Endpoints · 2mo ago↗ source

<![CDATA[Treatment Intensification Gains Momentum in mCSPC Management]]>

<![CDATA[During a recent OncLive Peer Exchange, prostate cancer experts discussed the evolving role of treatment intensification in mCSPC.]]>

onclive · 2mo ago↗ source

<![CDATA[FDA Approval of Brexu-Cel for R/R MCL Calls for Raised Awareness of CAR T-Cell Therapy Safety Considerations]]>

<![CDATA[Luhua (Michael) Wang, MD, discusses the FDA approval of brexu-cel in mantle cell lymphoma and what to know about CAR T-cell therapy in clinical practice.]]>

onclive · 2mo ago↗ source

Braveheart Bio's Hengrui-licensed cardiac drug scores second clinical win

Braveheart Bio said Monday that the heart muscle therapy it licensed from China’s Jiangsu Hengrui Pharmaceuticals has succeeded in a mid-stage trial for the same condition in which Cytokinetics rec…

Endpoints · 2mo ago↗ source

<![CDATA[Dr Randall on the Rationale for Investigating CSF-1R Inhibition in TGCT]]>

<![CDATA[R. Lor Randall, MD, FACS discusses safety and efficacy data from the MANEUVER trial, which evaluated pimicotinib in TGCT.]]>

onclive · 2mo ago↗ source

<![CDATA[Renal Cell Carcinoma: Real-World Factors in First-Line Treatment Selection]]>

<![CDATA[In this segment, Dr. Elizabeth Plimack and Dr. Yasser Ged discuss how real-world patient factors influence first-line treatment decisions in renal cell carcinoma. ]]>

onclive · 2mo ago↗ source

<![CDATA[Expanding ctDNA Applications to RCC and Germ Cell Tumors]]>

<![CDATA[Experts explain how ctDNA tracking in metastatic cancer guides therapy tweaks, flags relapse early, and where it fails in brain/peritoneal disease.]]>

onclive · 2mo ago↗ source

<![CDATA[RAPNO Criteria and MRI Assessment in PLGG: Recommendations vs. Real-World Practice]]>

<![CDATA[Learn how clinicians weigh symptoms, MRI changes and family goals to decide when a child’s tumor needs treatment—beyond simple size cutoffs.]]>

onclive · 2mo ago↗ source